| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
The primary targets of KLTWQELYQLKYKGI are VEGF receptors (VEGFRs). By binding to these receptors, it competes with VEGF, a key regulator of angiogenesis. This interaction leads to the activation of downstream signaling pathways that promote angiogenesis, endothelial cell proliferation, and migration. The peptide's ability to mimic VEGF makes it a valuable tool for studying angiogenesis and wound healing.
|
|---|---|
| ln Vitro |
In vitro, KLTWQELYQLKYKGI has demonstrated the capacity to induce capillary formation and organization. It binds to VEGF receptors and competes with VEGF for receptor binding. This activity promotes endothelial cell proliferation and migration, leading to the formation of new blood vessels. These in vitro studies confirm its proangiogenic activity.
|
| ln Vivo |
In vivo, KLTWQELYQLKYKGI is active in gastric ulcer healing in rodents when administered either orally or systemically. Its proangiogenic activity promotes the formation of new blood vessels, which is essential for tissue repair and wound healing. These in vivo studies provide evidence for its therapeutic potential in conditions such as gastric ulcers and other wounds.
|
| Enzyme Assay |
Cell-free assays for KLTWQELYQLKYKGI typically involve measuring its binding affinity to VEGF receptors using surface plasmon resonance (SPR) or ELISA. These assays are used to characterize the peptide's potency and specificity. Competitive binding assays are used to confirm that the peptide competes with VEGF for receptor binding.
|
| Cell Assay |
In vitro cellular assays are conducted to evaluate the functional activity of KLTWQELYQLKYKGI. Endothelial cells are treated with the peptide, and cell proliferation, migration, and tube formation are measured to assess its proangiogenic activity. These assays confirm that the peptide effectively promotes angiogenesis.
|
| Animal Protocol |
In vivo animal experiments typically involve rodent models of gastric ulcers or other wounds. Animals are administered the peptide via oral gavage or systemic injection. Wound healing is monitored over time to assess efficacy. These studies provide evidence for the peptide's therapeutic potential in wound healing.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of KLTWQELYQLKYKGI are characteristic of a peptide. It has a molecular weight of 1700.9 and is composed of 15 amino acids. The peptide is designed to be stable and bioavailable, with activity observed after both oral and systemic administration. Its stability and solubility are typical of small peptides.
|
| Toxicity/Toxicokinetics |
The toxicity profile of KLTWQELYQLKYKGI is not extensively documented, but it is likely to be similar to other proangiogenic agents. As a VEGF-mimicking peptide, it may have the potential to promote pathological angiogenesis if not properly regulated. Preclinical toxicology studies would typically involve acute and chronic dosing in animal models to assess safety margins.
|
| References | |
| Additional Infomation |
KLTWQELYQLKYKGI (QK) is a VEGF-mimicking peptide that is being investigated for its potential in wound healing and tissue repair. It has shown efficacy in promoting gastric ulcer healing in rodents. The peptide is a research tool for studying angiogenesis and the role of VEGF in various physiological and pathological processes. It is not approved for therapeutic use and is intended for research purposes only.
|
| Molecular Formula |
C92H143N21O23
|
|---|---|
| Molecular Weight |
1911.24674248695
|
| Exact Mass |
1910.067
|
| CAS # |
917760-16-8
|
| PubChem CID |
168679823
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
26
|
| Hydrogen Bond Acceptor Count |
27
|
| Rotatable Bond Count |
65
|
| Heavy Atom Count |
136
|
| Complexity |
3870
|
| Defined Atom Stereocenter Count |
16
|
| SMILES |
CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)N
|
| InChi Key |
ZHHXHKUQDPVCQO-MVXMSPHASA-N
|
| InChi Code |
InChI=1S/C92H143N21O23/c1-10-52(8)77(92(135)136)112-75(119)48-100-80(123)62(22-14-17-39-94)101-87(130)70(44-54-24-28-57(115)29-25-54)109-81(124)63(23-15-18-40-95)102-85(128)67(41-49(2)3)107-83(126)65(33-36-74(98)118)104-88(131)71(45-55-26-30-58(116)31-27-55)110-86(129)68(42-50(4)5)108-84(127)66(34-37-76(120)121)103-82(125)64(32-35-73(97)117)105-89(132)72(46-56-47-99-61-21-12-11-19-59(56)61)111-91(134)78(53(9)114)113-90(133)69(43-51(6)7)106-79(122)60(96)20-13-16-38-93/h11-12,19,21,24-31,47,49-53,60,62-72,77-78,99,114-116H,10,13-18,20,22-23,32-46,48,93-96H2,1-9H3,(H2,97,117)(H2,98,118)(H,100,123)(H,101,130)(H,102,128)(H,103,125)(H,104,131)(H,105,132)(H,106,122)(H,107,126)(H,108,127)(H,109,124)(H,110,129)(H,111,134)(H,112,119)(H,113,133)(H,120,121)(H,135,136)/t52-,53+,60-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,77-,78-/m0/s1
|
| Chemical Name |
(2S,3S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]acetyl]amino]-3-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5232 mL | 2.6161 mL | 5.2322 mL | |
| 5 mM | 0.1046 mL | 0.5232 mL | 1.0464 mL | |
| 10 mM | 0.0523 mL | 0.2616 mL | 0.5232 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
